BioCentury
ARTICLE | Tools & Techniques

Removing immunotoxin immunogenicity

April 14, 2011 7:00 AM UTC

Researchers at the National Cancer Institute have developed an approach to decrease the immunogenicity of therapeutic proteins that involves identifying and removing immunogenic B cell epitopes.1 As proof of concept, the group applied its method to MedImmune LLC's moxetumomab pasudotox

and engineered an analog that was nonimmunogenic in mice...